As we step into the latter half of 2025, China's pharmaceutical industry continues to assert its dominance on the global stage. With total pharmaceutical exports reaching new heights amid recovering global supply chains, Chinese companies are leading in the production and export of finished pharmaceutical products, including generics, vaccines, and innovative therapies. According to recent...

  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the official U.S. launch of Tryngolza™ (olezarsen), a novel, once-monthly RNA-targeted therapy for familial chylomicronemia syndrome (FCS).   The drug enters the market at an annual list price of $595,000, following its FDA approval in December 2024.       First FDA-Approved Olezarsen Therapy for...